Science & Technology > HCAB

Heavy Chain Only Antibodies (HCAbs)

  • Endogenous murine antibody expression eliminated
  • Human (or other mammalian) transgenes introduced, w/o CH1
  • Antigen challenge results in affinity matured HCAbs
  • Recovery from B cells or plasma cells (hybridoma or direct cDNA expression cloning)

hcabs01


HCAb Transgenic Mice Transgene

 

8V3 HCAb

 

 


HCAb Platform Evaluation

Potent HCAbs raised against a range of proteins including

  • cytokines,
  • bacterial and
  • viral targets

HCAbs isolated via:

  • expression cloning,
  • hybridomas,
  • phage display

Consistent isolation of HCAbs with affinities in the high pMolar to nMolar range
HCAb and derived Vh Profiles:

  • Soluble
  • Do not form aggregates in vitro
  • HCAbs have PK characteristics in vivo comparable to human H2L2 antibodies

HCAb & VH domains: Solubility & Aggregation

hcabs03


hcabs04

HCAb Platform: Applications

HCAbs can be used directly as simplified alternatives to conventional antibodies

The VH domains from HCAbs can yield “second generation” antibody-like therapeutics

  • Bispecific antibodies
  • Tetravalent antibodies

Harbour offers fully human HCAbs derived in vivo in transgenic mice

  • High affinity
  • Soluble
  • Stable

 

 

 

Harbour has a broad, robust patent portfolio covering human heavy chain rodent technology and human heavy chain constructs, to include six US Patents, three European Patents and numerous other patents and pending applications around the world.   These patent rights include US Patents #9,353,179, #9,346,877 and #8,921, 522, and European Patents #1776383 and #1864998.

 


BiSpecific BiValent HCAb

hcabs05

Tetravalent human Ab are soluble and do not aggregate

Harbour News

Upcoming Events

Join Mailing List

Name: 
Email: 
Company: 
Submit

Contact Us

Name: 
Email: 
Company: 
Message: 
Submit